| case report | Q2782326 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1053361495 |
| P356 | DOI | 10.1186/1756-0500-6-541 |
| P932 | PMC publication ID | 3878316 |
| P698 | PubMed publication ID | 24350786 |
| P5875 | ResearchGate publication ID | 259385782 |
| P2093 | author name string | Kazuhiko Nakagawa | |
| Junji Tsurutani | |||
| Yoshifumi Komoike | |||
| Tsutomu Iwasa | |||
| Atsuko Koyama | |||
| Hiromichi Matsuoka | |||
| Junko Tanizaki | |||
| P2860 | cites work | Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. | Q52846107 |
| Interactions between the chemotherapeutic agent eribulin mesylate (E7389) and P-glycoprotein in CF-1 abcb1a-deficient mice and Caco-2 cells | Q82912927 | ||
| The blood-brain barrier/neurovascular unit in health and disease | Q29616335 | ||
| Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites | Q33832954 | ||
| Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm | Q34632917 | ||
| A case of brain metastases from breast cancer treated with whole-brain radiotherapy and eribulin mesylate | Q36199963 | ||
| Mechanisms of the penetration of blood-borne substances into the brain | Q37313443 | ||
| Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine | Q37777290 | ||
| A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer | Q37944440 | ||
| Imaging blood-brain barrier dysfunction in animal disease models | Q38058371 | ||
| Atom-based enumeration: new eribulin analogues with low susceptibility to P-glycoprotein-mediated drug efflux | Q39247107 | ||
| Irradiation of rat brain reduces P-glycoprotein expression and function. | Q41945670 | ||
| Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane | Q46059531 | ||
| Regulation of permeability across the blood-brain barrier | Q48168818 | ||
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 541 | |
| P577 | publication date | 2013-12-18 | |
| P1433 | published in | BMC Research Notes | Q15762797 |
| P1476 | title | Regression of brain metastases from breast cancer with eribulin: a case report | |
| P478 | volume | 6 |
| Q90445060 | Activity of Eribulin Mesylate in Brain Metastasis from Breast Cancer: A Stone in a Pond? |
| Q35647947 | Brain Metastases from Breast Cancer and Response to Treatment with Eribulin: A Case Series |
| Q55457104 | Concomitant administration of radiation with eribulin improves the survival of mice harboring intracerebral glioblastoma. |
| Q42465330 | Eribulin Mesylate Combined with Local Treatment for Brain Metastasis from Breast Cancer: Two Case Reports. |
| Q39040318 | Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice |
| Q92107306 | Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts |
| Q54118354 | Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases. |
| Q38978443 | Retinal metastasis regression with eribulin in a heavily pretreated breast cancer patient |
| Q38897959 | Safety of eribulin mesylate and concomitant radiotherapy for metastatic breast cancer: a single-center experience. |
| Q103723872 | Treatment strategies for breast cancer brain metastases |
Search more.